Abstract
Evaluation of potential analgesic therapeutics and the elaboration of the neurobiology of pain have heavily relied on pain models developed in rodents. However, a limitation of rodents is their phylogenetic distance from humans, which could in part account for the failure of some preclinical findings to translate to clinical utility. By contrast, given their genetic closeness and phenotypic similarities to humans, it is suggested that there be greater utilization of non-human primates (NHP) in preclinical pain studies. Methods to induce chronic pain-like states and quantify changes in nociception that have been developed in rodents could be adapted to the NHP. Similarly, human experimental injury-induced sensitization, which attempts to temporarily mimic the neuropathology and symptoms observed in the chronic pain state, could be adapted to the NHP. The NHP could then serve as a platform to validate human experimental models as well as proof-of-concept studies. Beyond experimentally modeled pain states, a number of naturally occurring disease states, such as osteoarthritis, are expressed by NHP, which could be utilized for both hypothesis testing and proof-of-concept studies. While NHP studies are logistically cumbersome, it is envisioned that NHP pain models will add value to current preclinical data and greatly facilitate the discovery of novel analgesic treatments.
Keywords: Chronic pain, animal models, clinical relevance, drug discovery.
CNS & Neurological Disorders - Drug Targets
Title:Beyond Rodent Models of Pain: Non-Human Primate Models for Evaluating Novel Analgesic Therapeutics and Elaborating Pain Mechanisms
Volume: 12 Issue: 8
Author(s): Aldric T. Hama, Katsuo Toide and Hiroyuki Takamatsu
Affiliation:
Keywords: Chronic pain, animal models, clinical relevance, drug discovery.
Abstract: Evaluation of potential analgesic therapeutics and the elaboration of the neurobiology of pain have heavily relied on pain models developed in rodents. However, a limitation of rodents is their phylogenetic distance from humans, which could in part account for the failure of some preclinical findings to translate to clinical utility. By contrast, given their genetic closeness and phenotypic similarities to humans, it is suggested that there be greater utilization of non-human primates (NHP) in preclinical pain studies. Methods to induce chronic pain-like states and quantify changes in nociception that have been developed in rodents could be adapted to the NHP. Similarly, human experimental injury-induced sensitization, which attempts to temporarily mimic the neuropathology and symptoms observed in the chronic pain state, could be adapted to the NHP. The NHP could then serve as a platform to validate human experimental models as well as proof-of-concept studies. Beyond experimentally modeled pain states, a number of naturally occurring disease states, such as osteoarthritis, are expressed by NHP, which could be utilized for both hypothesis testing and proof-of-concept studies. While NHP studies are logistically cumbersome, it is envisioned that NHP pain models will add value to current preclinical data and greatly facilitate the discovery of novel analgesic treatments.
Export Options
About this article
Cite this article as:
Hama T. Aldric, Toide Katsuo and Takamatsu Hiroyuki, Beyond Rodent Models of Pain: Non-Human Primate Models for Evaluating Novel Analgesic Therapeutics and Elaborating Pain Mechanisms, CNS & Neurological Disorders - Drug Targets 2013; 12 (8) . https://dx.doi.org/10.2174/18715273113129990111
DOI https://dx.doi.org/10.2174/18715273113129990111 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin
CNS & Neurological Disorders - Drug Targets ACE Inhibition Prevents Diastolic Ca2+ Overload and Loss of Myofilament Ca2+ Sensitivity after Myocardial Infarction
Current Molecular Medicine Sepsis Pathophysiology and Anesthetic Consideration
Cardiovascular & Hematological Disorders-Drug Targets Limited Hypotensive Effect of Sildenafil in a High-Risk Population: A Preliminary Report
Current Drug Safety Aldosterone Receptor Antagonists and Cardiovascular Disease: Do We Need a Change of the Guard?
Cardiovascular & Hematological Agents in Medicinal Chemistry Calcium as a Molecular Target in Angiogenesis
Current Pharmaceutical Design Design, Synthesis and Antimicrobial Properties of Novel 3,3a,4,5,6,7- Hexahydroindazole and Arylthiazolylpyrazoline Derivatives
Medicinal Chemistry Synthesis and DPPH Radical Scavenging Activity of 5-Arylidene-N,Ndimethylbarbiturates
Medicinal Chemistry Restoring the Dysfunctional Endothelium
Current Pharmaceutical Design Hypertension in Patients with Severe Aortic Stenosis: Emphasis on Antihypertensive Treatment and the Risk of Syncope
Current Hypertension Reviews Editorial (Thematic Issue: Medicinal Chemistry from Fungi and Back: Discovery of Novel Anti-Fungal Drugs and Mycotherapy of Cancer and Other Diseases with Fungal Metabolites)
Current Topics in Medicinal Chemistry Ethnopharmacology, Phytochemistry and Biological Activities of Native Chilean Plants
Current Pharmaceutical Design Cardiovascular Side Effects of New Antidepressants and Antipsychotics: New Drugs, old Concerns?
Current Pharmaceutical Design Nitric Oxide-NASIDS Donor Prodrugs as Hybrid Safe Anti-inflammatory Agents
Current Topics in Medicinal Chemistry The 5-HT1B Receptor: A Novel Target for the Pathophysiology of Depression
Current Drug Targets Phosphodiesterase Type 5 Inhibitors: Unmet Needs
Current Pharmaceutical Design A Systematic Review of Randomized Controlled Trials Examining the Nephroprotective Properties of Antihypertensive Medications
Current Hypertension Reviews Neurological Aspects of Medical Use of Cannabidiol
CNS & Neurological Disorders - Drug Targets Synthetic Cannabinoids as Drugs of Abuse
Current Drug Abuse Reviews The Use of Dexmedetomidine in Anesthesia and Intensive Care: A Review
Current Pharmaceutical Design